A progressive translational mouse model of human valosin-containing protein disease: The VCPR155H/+ mouse

Muscle and Nerve

Volumn 47, Issue 2, 2013, Pages 260-270

  Nalbandian, Angèle ^a   Llewellyn, Katrina J ^a   Badadani, Mallikarjun ^a   Yin, Hong Z ^a   Nguyen, Christopher ^a   Katheria, Veeral ^a   Watts, Giles ^b   Mukherjee, Jogeshwar ^a   Vesa, Jouni ^a   Caiozzo, Vincent ^c   Mozaffar, Tahseen ^a,c   Weiss, John H ^a   Kimonis, Virginia E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cytoplasmic inclusions; Frontotemporal dementia; Inclusion body myopathy; Molecular genetics; Motor neuron degeneration; Paget disease of bone; Pathology; Valosin containing protein

Indexed keywords

UBIQUITIN; VALOSIN CONTAINING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL INCLUSION; CONTROLLED STUDY; CYTOPLASM; DEGENERATIVE DISEASE; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; LONG BONE; MICRO-COMPUTED TOMOGRAPHY; MOTONEURON; MOUSE; MUSCLE STRENGTH; MUSCLE WEAKNESS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPINAL CORD; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BRAIN; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FRONTOTEMPORAL DEMENTIA; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MYOSITIS, INCLUSION BODY; OSTEITIS DEFORMANS; SPINAL CORD;

EID: 84873029243     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23522     Document Type: Article

References (70)

1. Kimonis VE, Kovach MJ, Waggoner B, Leal S, Salam A, Rimer L, et al. Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone. Genet Med 2000; 2: 232-241.
2. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genet 2004; 36: 377-381.
3. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 2008; 146A: 745-757.
4. Watts GD, Thorne M, Kovach MJ, Pestronk A, Kimonis VE. Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes. Neuromuscul Disord 2003; 13: 559-567.
5. Kimonis VE, Fulchiero E, Vesa J, Watts G. VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim Biophys Acta 2008; 1782: 744-748.
6. Weihl CC Temiz P, Miller SE, Watts G, Smith C, Forman M, et al. TDP-43 accumulation in IBM muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79: 1186-1189.
7. Vesa J, Su H, Watts GD, Krause S, Walter MC, Martin B, et al. Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul Disord 2009; 19: 766-772.
8. Shaw CE. Capturing VCP: another molecular piece in the ALS jigsaw puzzle. Neuron 2010; 68: 812-814.
9. Leigh PN, Wijesekera LC. Motor neuron disease: focusing the mind on ALS: updated practice parameters. Nat Rev Neurol 2010; 6: 191-192.
10. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857-864.
11. Abramzon Y, Johnson JO, Scholz SW, Taylor JP, Brunetti M, Calvo A, et al. Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33: 1848.e15-20.
12. Tiloca C, Ratti A, Pensato V, Castucci A, Soraru G, Del Bo R, et al. Mutational analysis of VCP gene in familial amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33: 630.e1-2.
13. Williams KL, Solski JA, Nicholson GA, Blair IP. Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2011; 33: 1488.e15-16.
14. Farpour F, Tehranzadeh J, Donkervoort S, Smith C, Martin B, Vanjara P, et al. Radiological features of Paget disease of bone associated with VCP myopathy. Skeletal Radiol 2012; 41; 329-337.
15. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 2008; 146: 745-757.
16. Arnold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging 2000; 21: 913-919.
17. Turner RS, Kenyon LC, Trojanowski JQ, Gonatas N, Grossman M. Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Ann Neurol 1996; 39: 166-173.
18. Zhukareva V, Vogelsberg-Ragaglia V, van Deerlin VM, Bruce J, Shuck T, Grossman M, et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol 2001; 49: 165-175.
19. DeLaBarre B, Brunger AT. Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nat Struct Biol 2003; 10: 856-863.
20. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001; 3: 740-744.
21. Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, et al. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. J Cell Biol 2009; 187: 875-888.
22. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. Neuromuscul Disord 2009; 19: 308-315.
23. Tang WK, Li D, Li CC, Esser L, Dai R, Guo L, et al. A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants. EMBO J 2010; 29: 2217-2229.
24. Ju JS, Weihl CC. Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet 2010; 19: R38-45.
25. Hubbers CU, Clemen CS, Kesper K, Boddrich A, Hofmann A, Kamarainen O, et al. Pathological consequences of VCP mutations on human striated muscle. Brain 2007; 130: 381-393.
26. Nalbandian A, Donkervoort S, Dec E, Badadani M, Katheria V, Rana P, et al. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci 2011; 45; 522-531.
27. Muller JM, Meyer HH, Ruhrberg C, Stamp GW, Warren G, Shima DT. The mouse p97 (CDC48) gene. Genomic structure, definition of transcriptional regulatory sequences, gene expression, and characterization of a pseudogene. J Biol Chem 1999; 274: 10154-10162.
28. Muller JM, Deinhardt K, Rosewell I, Warren G, Shima DT. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochem Biophys Res Commun 2007; 354: 459-465.
29. Weihl CC, Miller SE, Hanson PI, Pestronk A. Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice. Hum Mol Genet 2007; 16: 919-928.
30. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19: 1741-1755.
31. Badadani M, Nalbandian A, Watts GD, Vesa J, Kitazawa M, Su H, et al. VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PloS One 2010; 5.
32. Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, et al. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ 2001; 8: 977-984.
33. Kobayashi T, Tanaka K, Inoue K, Kakizuka A. Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells. J Biol Chem 2002; 277: 47358-47365.
34. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11: 709-719.
35. Cook GJ, Blake GM, Marsden PK, Cronin B, Fogelman I. Quantification of skeletal kinetic indices in Paget's disease using dynamic 18F-fluoride positron emission tomography. J Bone Miner Res 2002; 17: 854-859.
36. Bays NW, Hampton RY. Cdc48-Ufd1-Npl4: stuck in the middle with Ub. Curr Biol 2002; 12: R366-71.
37. Fu X, Ng C, Feng D, Liang C. Cdc48p is required for the cell cycle commitment point at Start via degradation of the G1-CDK inhibitor Far1p. J Cell Biol 2003; 163: 21-26.
38. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005; 120: 73-84.
39. Ye Y, Meyer HH, Rapoport TA. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 2001; 414: 652-656.
40. Frohlich KU, Fries HW, Rudiger M, Erdmann R, Botstein D, Mecke D. Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression. J Cell Biol 1991; 114: 443-453.
41. Lamb JR, Fu V, Wirtz E, Bangs JD. Functional analysis of the trypanosomal AAA protein TbVCP with trans-dominant ATP hydrolysis mutants. J Biol Chem 2001; 276: 21512-21520.
42. Leon A, McKearin D. Identification of TER94, an AAA ATPase protein, as a Bam-dependent component of the Drosophila fusome. Mol Biol Cell 1999; 10: 3825-3834.
43. Wojcik C, Yano M, DeMartino GN. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 2004; 117: 281-292.
44. Vesa J, Su H, Fan W, Watts GD, Krause S, Walter MC, et al. Mechanisms of p97/VCP associated inclusion body and vacuolar myopathy: studies in human myoblasts. Neuromuscul Disord 2009; 19; 766-772.
45. Custer SK, Neumann M, Lu H, Wright AC, Taylor JP. Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. Hum Mol Genet 2010; 19: 1741-1755.
46. Kimonis VE, Watts GD. Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord 2005; 19(suppl 1): S44-47.
47. Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, et al. Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 2001; 74: 458-475.
48. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 2007; 66: 152-157.
49. Kakizuka A. Roles of VCP in human neurodegenerative disorders. Biochem Soc Trans 2008; 36: 105-108.
50. Mizuno Y, Hori S, Kakizuka A, Okamoto K. Vacuole-creating protein in neurodegenerative diseases in humans. Neurosci Lett 2003; 343: 77-80.
51. Guyant-Marechal L, Laquerriere A, Duyckaerts C, Dumanchin C, Bou J, Dugny F, et al. Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology 2006; 67: 644-651.
52. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477: 211-215.
53. DeJesus-Hernandez M, Desaro P, Johnston A, Ross OA, Wszolek ZK, Ertekin-Taner N, et al. Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology 2011; 77: 1102-1103.
54. Gijselinck I, van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012; 11: 54-65.
55. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268.
56. van Langenhove T, van der Zee J, van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med (in press).
57. Bergamini E, Cavallini G, Donati A, Gori Z. The role of autophagy in aging: its essential part in the anti-aging mechanism of caloric restriction. Ann NY Acad Sci 2007; 1114: 69-78.
58. Eskelinen EL. Maturation of autophagic vacuoles in mammalian cells. Autophagy 2005; 1: 1-10.
59. Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC, Kroemer G. To die or not to die: that is the autophagic question. Curr Mol Med 2008; 8: 78-91.
60. Scarlatti F, Granata R, Meijer AJ, Codogno P. Does autophagy have a license to kill mammalian cells? Cell Death Differ 2009; 16: 12-20.
61. Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep 2003; 3: 64-69.
62. Tanaka Y, Guhde G, Suter A, Eskelinen EL, Hartmann D, Lullmann-Rauch R, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 2000; 406: 902-906.
63. Stypmann J, Janssen PM, Prestle J, Engelen MA, Kogler H, Lullmann-Rauch R, et al. LAMP-2 deficient mice show depressed cardiac contractile function without significant changes in calcium handling. Basic Res Cardiol 2006; 101: 281-291.
64. Daroszewska A, van 't Hof RJ, Rojas JA, Layfield R, Landao-Basonga E, Rose L, et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Hum Mol Genet 2011; 20: 2734-2744.
65. Dell'Atti C, Cassar-Pullicino VN, Lalam RK, Tins BJ, Tyrrell PN. The spine in Paget's disease. Skelet Radiol 2007; 36: 609-626.
66. Nguyen BD, Ram PC, Roarke MC. PET/CT imaging of metastatic deposit in vertebral Paget's disease. Clin Nucl Med 2005; 30: 359-360.
67. Niederkohr RD, Gambhir SS. F-18 FDG PET/CT imaging of extramammary Paget disease of the perianal region. Clin Nucl Med 2006; 31: 561-563.
68. Altman RD, Brown M, Gargano F. Low back pain in Paget's disease of bone. Clin Orthop Rel Res 1987; 152-161.
69. Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology (Oxf) 2004; 43: 955-959.
70. Meunier PJ, Salson C, Mathieu L, Chapuy MC, Delmas P, Alexandre C, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Rel Res 1987; 37-44.